Axil Capital
Axil Capital is a venture capital firm specializing in biomedical and healthcare technology investments. They focus on supporting the growth of early-stage ventures and leveraging their global network to create synergies between the Japanese and global biotech ecosystems. Their investments span the full spectrum of the life science industry, from seed to crossover rounds.
Founded 2017 · Venture Capital
Tokyo (
Japan)
Japan)Investment Stages
Series A
Series B
Markets
Biopharmaceuticals
Platform technologies
Medical devices
Digital health
Healthcare services
Artificial Intelligence (AI)
Pharmaceutical
Robotics
Portfolio Companies
LinqMed, Y4, MabGenesis, Pulmotect, CynosBio (formerly Hirosaki LI), Techsomed, Elixiron, GEXVal, FRAXA, Cranebio, Luca Science, Jolly Good, United Immunity, Perseus Proteomics, Allgenesis, Abrax Japan
Related VC firms in Japan
Abies Ventures
Robotics, Mobility, Computing, Communications, New Materials, Climate Tech, Space
Accord Ventures
IT-enabled platform businesses, IoT, AI, Fintech
Airbus Ventures
autonomous mobility, electrification, low-carbon economy, advanced materials, manufacturing systems, next-generation computing, sensing, security